US Approves Trump's Ebola Drug From Regeneron, A Manufacturer That Creates Mixed Antibodies To Trump's COVID-19

Ebola virus handling picture (Source: Commons Wikimedia)

JAKARTA - The United States Food and Drug Administration (FDA) announced that it has approved a mixture of three antibodies from Regeneron Pharmaceuticals as the first treatment for the Ebola virus.

Launching Fox Business , Thursday, October 15, the mixture is Inmazeb, a drug that is injected into a vein. The drug has been approved for use by adults and children after clinical trials of 382 people infected with the Ebola zaire virus.

"What we are doing today demonstrates the commitment the FDA is making to respond to threats to public health, both at home and abroad, based on science and data," said FDA Commissioner Stephen Hahn in a statement.

Previously, the FDA had approved Ervebo as the first Ebola disease prevention vaccine. Approval given in December 2019.

Regeneron's company said it had also spoken with the FDA about granting emergency use permits for a mixture of two antibodies it was developing for COVID-19. The mixture of the two antibodies in question is the one given to US President Donald Trump.

The two Regeneron treatments are a class of drugs known as "monoclonal antibodies," which are copies of antibodies made from antibodies of the immune system as the primary weapon against infection.